U.S. Markets closed

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4

Zacks Equity Research

Esperion Therapeutics, Inc. ESPR incurred a loss of $2.24 per share in the fourth quarter of 2018, wider than the Zacks Consensus Estimate of $1.33. The company’s loss was $1.44 per share in the year-ago period.

With no approved products in its portfolio, the company did not generate any revenues in the reported quarter. However, the company has filed regulatory applications seeking approval for its key candidates – bempedoic acid monotherapy and bempedoic acid / Merck’s MRK Zetia (ezetimibe) combination pill.

Esperion’s shares have lost significant value in the past year, falling 40.1%.

Quarter in Details

Research and development (R&D) expenses surged 47.9% from the year-ago period to $49.5 million. The rise was primarily due to higher cost needed to support development of bempedoic acid monotherapy and combination therapy, including five pivotal studies and one cardiovascular outcomes study.

General and administrative (G&A) expenses more than doubled year over year to $11.2 million primarily driven by costs related to support pre-commercialization activities for both the candidates.

As of Dec 31, 2018, Esperion had cash, cash equivalents and investment securities of $136.3 million compared with $273.6 million as of Dec 31, 2017.

Full-Year Results

Esperion incurred a loss of $7.54 per share, wider than the year-ago loss of $6.98 due to increase in operating expense to support the progress of its pipeline. The company generated no revenues during the period.

2019 Guidance

Esperion provided guidance for collaborations revenues and operating expenses in 2019. The company expects income from collaboration and license agreement to be $150 million. R&D expense is estimated between $115 million and $120 million while G&A expense is expected in the range of $60-$65 million.

Pipeline Update

In February 2019, Esperion submitted regulatory applications in the United States and EU seeking approval for bempedoic acid monotherapy as well as bempedoic acid/Zetia combination tablet. The regulatory applications, seeking approval for cholesterol (LDL-C) lowering indications, were filed based on data from several pivotal studies evaluating the candidates.

Data from four phase III studies evaluating bempedoic acid monotherapy, presented previously, demonstrated that treatment with the therapy led to additional 18% reduction in LDL-C over 31% LDL-C reduction in statin-treated patients on maximally tolerated statin.

Data from the phase III study evaluating bempedoic acid/Zetia combination pill showed that the combination regimen reduced bad cholesterol by 35% compared with 24% for Zetia (20mg) monotherapy, 20% for bempedoic acid and 3% for placebo in patients receiving maximally tolerated statins.

In January 2019, Esperion announced an agreement with Daiichi Sankyo Europe, granting exclusive rights to the latter to commercialize bempedoic acid and the bempedoic acid/Zetia combination pill in Europe and Switzerland. The company is eligible to receive up to $900 million in payments from Daiichi including an upfront payment of $150 million and additional future milestone and royalty payments.

Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise

 

Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise | Esperion Therapeutics, Inc. Quote

Zacks Rank & Stocks to Consider

Esperion currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the healthcare sector include Celgene Corporation CELG and Genomic Health, Inc. GHDX. While Celgene sports a Zacks Rank #1 (Strong Buy), Genomic Health carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Celgene’s earnings estimates have been revised 5.3% upward for 2019 and 9.2% for 2020 over the past 60 days. The stock has rallied almost 29.7% so far this year.

Genomic Health’s earnings estimates have moved north 17.9% for 2019 and 13.9% for 2020 over the past 60 days. The stock has gained 17.9% so far this year.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Celgene Corporation (CELG) : Free Stock Analysis Report
 
Genomic Health, Inc. (GHDX) : Free Stock Analysis Report
 
Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research